BMS-986104 is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 3 clinical trials, of which 2 were completed, and 1 is ongoing.
BMS-986104 acts as sphingosine 1-phosphate (S1P) receptor 1 agonist. It binds to S1P1 and blocks the capacity of lymphocytes to release from lymph nodes, causing redistribution and thereby reduces the infiltration of pathogenic lymphocyte cells, involved in immuno-suppression. The drug candidate also induces remyelinating effects on lysophosphatidylcholine (LPC)-induced demyelination without interacting with the complex systemic immune system and prevents lymphocyte egress from lymphoid organs, thereby inhibiting CNS attack by pathogenic lymphocytes.
The revenue for BMS-986104 is expected to reach a total of $189m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BMS-986104 NPV Report.
BMS-986104 is originated and owned by Bristol-Myers Squibb.
BMS-986104 is under development for the treatment of atopic dermatitis and rheumatoid arthritis. The drug candidate is administered orally. It acts by targeting sphingosine 1-phosphate (S1P1) receptor. It was also under development inflammatory bowel disease and multiple sclerosis.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.
Quick View – BMS-986104
|Highest Development Stage|